Observational Study of Meloxicam in Any Labeled Indication

N/ACompletedNCT02182739

Boehringer Ingelheim13,039 enrolled

Overview

Evaluation on the amelioration of symptom intensity of the indication and to evaluate drug tolerability.

Study Type

OBSERVATIONAL

Enrollment

13,039

tablets or injectable solution

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients according to the physicians medical criteria on the labeled indications for Meloxicam Exclusion Criteria: * none

Change in assessment of intensity of pain on a 4-point verbal rating scale

Time frame: up to 1 year

Assessment of tolerability on a 4-point scale

Time frame: up to 1 year

Number of patients with adverse events

Time frame: up to 1 year

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.